Skip to search formSkip to main contentSkip to account menu

SGN-15

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
7299 Background: NSCLC cells express tumor antigens, including Lewis Υ (Ley). SGN-15 is a novel antibody-drug conjugate that… 
2004
2004
7039 Background: Docetaxel (Doc) remains the only FDA approved second line chemotherapy for NSCLC, but response rates and… 
2003
2003
OBJECTIVEThe SGN-15 monoclonal antibody-doxorubicin immunoconjugate is toxic to LewisY antigen-expressing cells and is effective… 
2003
Review
2001
Review
2001
  • S. Smith
  • Current opinion in molecular therapeutics
  • 2001
  • Corpus ID: 27000520
Seattle Genetics is developing SGN-15 (BMS-182248, BR96-DOX), a monoclonal antibody-doxorubicin conjugate licensed from Bristol…